Novavax’ NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/3/2026

1. SNOW
2. AVGO
3. HPE
4. RARE
5. FIVE
6. VRTS
7. NTSK
8. NTAP
9. OLLI
10. CRWD

Go back to Novavax’ NanoFlu Achieves All Primary Endpoints In Phase 3 Clinical Trial
Novavax, Inc. (NASDAQ: NVAX) Delayed: 10.32 --0 (-0%)
Previous Close $10.32    52 Week High $9.23 
Open $10.32    52 Week Low $1.16 
Day High $10.32    P/E N/A 
Day Low $10.32    EPS $-0.30 
Volume 19,138       

Novavax, Inc. (NASDAQ: NVAX) Delayed: 10.32 --0 (-0%)
Previous Close $10.32    52 Week High $9.23 
Open $10.32    52 Week Low $1.16 
Day High $10.32    P/E N/A 
Day Low $10.32    EPS $-0.30 
Volume 19,138